Search This Blog

Saturday, March 5, 2016

Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)

Filing Based on Phase 2 Study Showing BLINCYTO Provides Meaningful Therapeutic Benefits in Difficult-to-Treat Type of Pediatric Acute Lymphoblastic Leukemia



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.